Similar articles

• A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.

  Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Olivieri NF. Perrine SP, et al. N Engl J Med. 1993 Jan 14;328(2):81-6. doi: 10.1056/NEJM199301143280202. N Engl J Med. 1993. PMID: 7677966 Clinical Trial.
• Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.

  Pearson HA. Pearson HA. Adv Pediatr. 1996;43:309-34. Adv Pediatr. 1996. PMID: 8794181 Review. No abstract available.
• Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.

  Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R. Italia K, et al. Blood Cells Mol Dis. 2009 Jan-Feb;42(1):25-31. doi: 10.1016/j.bcmd.2008.08.003. Epub 2008 Oct 26. Blood Cells Mol Dis. 2009. PMID: 18954999 Clinical Trial.
• Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders.

  Perrine SP, Olivieri NF, Faller DV, Vichinsky EP, Dover GJ, Ginder GD. Perrine SP, et al. Am J Pediatr Hematol Oncol. 1994 Feb;16(1):67-71. Am J Pediatr Hematol Oncol. 1994. PMID: 7508690
• Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?

  Fathallah H, Sutton M, Atweh GF. Fathallah H, et al. Ann N Y Acad Sci. 2005;1054:228-37. doi: 10.1196/annals.1345.029. Ann N Y Acad Sci. 2005. PMID: 16339670 Review.